In the last trading session, 1.03 million 4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares changed hands as the company’s beta touched 2.75. With the company’s per share price at $2.51 changed hands at -$0.14 or -5.28% during last session, the market valuation stood at $116.22M. FDMT’s last price was a discount, traded about -1065.74% off its 52-week high of $29.26. The share price had its 52-week low at $2.46, which suggests the last value was 1.99% up since then. When we look at 4D Molecular Therapeutics Inc’s average trading volume, we note the 10-day average is 0.91 million shares, with the 3-month average coming to 823.03K.
Analysts gave the 4D Molecular Therapeutics Inc (FDMT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.75. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended FDMT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. 4D Molecular Therapeutics Inc’s EPS for the current quarter is expected to be -0.86.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
Instantly FDMT was in red as seen at the end of in last trading. With action -16.05%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -54.94%, with the 5-day performance at -16.05% in the red. However, in the 30-day time frame, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is -35.56% down. Looking at the short shares, we see there were 5.03 million shares sold at short interest cover period of 7.4 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 58.17% from its current market value. According to analyst projections, FDMT’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -139.04% plunge from its current level, while the stock would need to soar -139.04% for it to hit the projected low.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Year-over-year growth is forecast to reach 13,019.24% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 529.67k. 6 analysts are of the opinion that 4D Molecular Therapeutics Inc’s revenue for the current quarter will be 525.83k. The company’s revenue for the corresponding quarters a year ago was 28k and 5k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1,791.68%. The estimates for the next quarter sales put growth at 10,416.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.89%. The 2025 estimates are for 4D Molecular Therapeutics Inc earnings to decrease by -20.38%, but the outlook for the next 5-year period is at -4.47% per year.
FDMT Dividends
4D Molecular Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-27.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.89% of 4D Molecular Therapeutics Inc shares while 103.16% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 107.33%. There are 103.16% institutions holding the 4D Molecular Therapeutics Inc stock share, with RA CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 9.2221% of the shares, roughly 5.1 million FDMT shares worth $107.01 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.8579% or 4.9 million shares worth $102.79 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.54 shares estimated at $3.86 million under it, the former controlled 3.32% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.82% of the shares, roughly 1.3 shares worth around $3.27 million.
